novel treatments

Research in Review

Novel TKI Therapy Plus Gemcitabine Does Not Improve OS in Pancreatic Cancer

03/09/2017

JCP Editors

A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to a study...

A new...

03/09/2017

Journal of Clinical Pathways

Research in Review

Study: Newer NSCLC Therapies Have Limited Real-World Survival Benefit, High Costs

02/14/2017

JCP Editors

Therapies recently approved to treat advanced-stage non-small cell lung cancer (NSCLC) confer an average of 1.5-month survival increase and an $8,000 increase in outpatient spending per patient, according to a study...

...

02/14/2017

Journal of Clinical Pathways

Research in Review

Best Treatment Course for Brain Metastases in EGFR Lung Cancer Identified

01/27/2017

JCP Editors

The best sequence of treatment strategies has been identified for patients with epidermal growth factor receptor (EGFR)-mutant lung cancer and brain metastases, according to an article published in the Journal of...

The...

01/27/2017

Journal of Clinical Pathways

Research in Review

Combination Treatment Improves Survival for BRAF-Mutant Metastatic Colorectal Cancer

01/26/2017

JCP Editors

The addition of BRAF-inhibitor vemurafenib to irinotecan and cetuximab chemotherapy treatment improves progression-free survival (PFS) for patients with BRAF-mutant metastatic colorectal cancer, according to a...

The...

01/26/2017

Journal of Clinical Pathways

Research in Review

Immune Checkpoint Inhibitor New Standard of Care for MSI-H Metastatic Colorectal Cancer

01/25/2017

JCP Editors

The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal...

The...

01/25/2017

Journal of Clinical Pathways

Research in Review

Induction Therapy With Clofarabine Shows No Survival Benefit for AML

01/16/2017

JCP Editors

Adding clofarabine to standard induction therapy shows no effect on survival for patients with newly diagnosed acute myeloid leukemia (AML), according to a study published in Blood. Standard induction treatment with...

Adding...

01/16/2017

Journal of Clinical Pathways

Research in Review

Three-Drug Regimen Does Not Improve Prostate Cancer Survival

01/05/2017

JCP Editors

Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...

...

01/05/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Plus Bortezomib Improves Survival for Patients With Multiple Myeloma

12/29/2016

JCP Editors

The addition of bortezomib to lenalidomide with dexamethasone treatment significantly improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma, according to new clinical...

The...

12/29/2016

Journal of Clinical Pathways

Research in Review

Ibuprofen May Lower Risk of Lung Cancer Death Among Smokers

12/21/2016

JCP Editors

Regular ibuprofen intake may lower the risk of lung cancer death among individuals with current or past histories of smoking, according to a new study. ----- Related Content New Lung Cancer Biomarker...

...

12/21/2016

Journal of Clinical Pathways

Research in Review

Trastuzumab Biosimilar Approval Could Improve Access to Treatment For Breast Cancer

12/05/2016

JCP Editors

The potential FDA approval of a new biosimilar to trastuzumab may help increase access to the treatment, which is recommended as first-line therapy for patients with ERBB2 (HER2)-positive breast...

The...

12/05/2016

Journal of Clinical Pathways